scispace - formally typeset
R

Ranjani Manjunath

Researcher at GlaxoSmithKline

Publications -  5
Citations -  399

Ranjani Manjunath is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Epilepsy & Dopaminergic. The author has an hindex of 5, co-authored 5 publications receiving 357 citations.

Papers
More filters
Journal ArticleDOI

Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: Survey of patients with epilepsy and physicians

TL;DR: Patient-oriented epilepsy treatment programs and clear communication strategies to promote self-management and patients' understanding of epilepsy are essential to maximizing treatment and quality of life outcomes while also minimizing economic costs.
Journal ArticleDOI

Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample

TL;DR: It is important for physicians to carefully screen patients for changes in RLS Symptoms for as long as they are on dopamine agents, with particular attention paid to those patients who present with the most severe RLS symptoms prior to treatment initiation.
Journal ArticleDOI

Adolescent and Caregiver Experiences With Epilepsy

TL;DR: An adolescent-centered epilepsy management program may help alleviate concerns and also help the adolescent independently manage their epilepsy as they transition into adulthood.
Journal ArticleDOI

Prospective, open-label trial measuring satisfaction and convenience of two formulations of lamotrigine in subjects with mood disorders.

TL;DR: Lamotrigine ODT was found to be significantly more convenient to use than lamotigine immediate-release and both formulations were associated with good satisfaction, and may be a treatment option for patients who have difficulty swallowing medication.
Journal Article

Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists.

TL;DR: This study assessed the direct economic burden of restless legs syndrome among patients treated with dopamine agonists using a large United States managed care database and found relatively low costs associated with RLS treatment.